Eli Lilly and Company and Innovent Biologics, Inc., announced one of the largest biotech drug development collaborations in China thus far today in Beijing. Under the agreement, Lilly and Innovent will collaborate to develop and potentially commercialize at least three cancer treatments over the next decade. The agreement creates possible new treatment options for cancer patients, …read more.

Eli Lilly and Company (NYSE: LLY) has received its third US Food and Drug Administration (FDA) approval for CYRAMZA® (ramucirumab). Specifically, CYRAMZA is now also indicated in combination with docetaxel, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Patients with epidermal growth factor receptor (EGFR) or …read more.